WO2005094415A3 - Recombinant vectors and methods for inducing an immune response - Google Patents

Recombinant vectors and methods for inducing an immune response Download PDF

Info

Publication number
WO2005094415A3
WO2005094415A3 PCT/US2005/003903 US2005003903W WO2005094415A3 WO 2005094415 A3 WO2005094415 A3 WO 2005094415A3 US 2005003903 W US2005003903 W US 2005003903W WO 2005094415 A3 WO2005094415 A3 WO 2005094415A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immune response
recombinant vectors
inducing
vectors
Prior art date
Application number
PCT/US2005/003903
Other languages
French (fr)
Other versions
WO2005094415A2 (en
Inventor
Scott E Hensley
Hildegund C J Ertl
Original Assignee
Wistar Inst
Scott E Hensley
Hildegund C J Ertl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Scott E Hensley, Hildegund C J Ertl filed Critical Wistar Inst
Publication of WO2005094415A2 publication Critical patent/WO2005094415A2/en
Publication of WO2005094415A3 publication Critical patent/WO2005094415A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to recombinant vectors with additional, replacement, or modified viral-associated RNA nucleic acid sequences. Methods of using such vectors for modulating an immune response or for treating genetic or acquired diseases are also provided.
PCT/US2005/003903 2004-02-06 2005-02-07 Recombinant vectors and methods for inducing an immune response WO2005094415A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54243104P 2004-02-06 2004-02-06
US60/542,431 2004-02-06

Publications (2)

Publication Number Publication Date
WO2005094415A2 WO2005094415A2 (en) 2005-10-13
WO2005094415A3 true WO2005094415A3 (en) 2007-03-08

Family

ID=35064352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003903 WO2005094415A2 (en) 2004-02-06 2005-02-07 Recombinant vectors and methods for inducing an immune response

Country Status (1)

Country Link
WO (1) WO2005094415A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008262478B9 (en) * 2007-05-29 2014-06-19 Aldevron, L.L.C. Vectors and methods for genetic immunization

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAI J. ET AL.: "RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model", MOL. THER., vol. 6, no. 6, December 2002 (2002-12-01), pages 770 - 782, XP003008464 *
BARCELLINI-COUGET S. ET AL.: "3'-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes", ANTICENSE NUCLEIC ACID DRUG DEV., vol. 8, 1998, pages 379 - 390, XP009025517 *
CAGNON L. ET AL.: "Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts", ANTISENSE NUCLEIC ACID DRUG DEV., vol. 10, 2000, pages 251 - 261, XP002366542 *
ELOIT M. ET AL.: "High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes", J. VIROL., vol. 71, no. 7, July 1997 (1997-07-01), pages 5375 - 5381, XP001007095 *
KITAJEWSKI J. ET AL.: "Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase", CELL, vol. 45, 25 April 1986 (1986-04-25), pages 195 - 200, XP003008463 *
MATHEWS M.B. ET AL.: "Adenovirus virus-associated RNA and translation control", J. VIROLOGY, vol. 65, no. 11, November 1991 (1991-11-01), pages 5657 - 5662, XP000602202 *
MEDINA M.F. ET AL.: "RNA-polymerase III-driven expression cassettes in human gene therapy", CURR. OPIN. MOL. THER., vol. 1, no. 5, 1999, pages 580 - 594, XP001055319 *
RAHMAN A. ET AL.: "Effect of single-base substitution in the central domain of virus-associated RNA I on its function", J. VIROL., vol. 69, no. 7, July 1995 (1995-07-01), pages 4299 - 307, XP002161423 *

Also Published As

Publication number Publication date
WO2005094415A2 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
WO2003080807A3 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2007117438A3 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
EP1569695A4 (en) Antisense modulation of apolipoprotein b expression
WO2006123097A3 (en) Improved expression elements
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
DE60235297D1 (en) LPS-RESISTANT CHS1 / BEIGE-SIMILAR ANCHOR GENES AND THERAPEUTIC APPLICATIONS THEREOF
IL169367A0 (en) Defensin proteins
WO2006047728A3 (en) Bmp gene and fusion protein
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2006016172A3 (en) Cell surface glycoprotein
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
WO2009083968A8 (en) Novel protein
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO2002079405A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2002074974A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2003033725A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2002079430A3 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
WO2002077164A3 (en) Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase